{"article_link": "https://doi.org/10.1038/s41591-021-01329-2", "data": [{"id": "data_1", "omics": "Transcriptomics", "link": "https://covid19cellatlas.org/", "format": "h5ad", "source": "ArrayExpress", "public_id": "E-MTAB-10026", "description": "Single-cell RNA-seq data from PBMCs, processed with STAR alignment and UMI deduplication."}, {"id": "data_2", "omics": "Proteomics", "link": "https://covid19cellatlas.org/", "format": "h5ad", "source": "Custom CITE-seq", "public_id": "E-MTAB-10026", "description": "Surface protein expression data using TotalSeq-C antibodies, processed with doublet removal and background correction."}, {"id": "data_3", "omics": "Immunomics (TCR)", "link": "https://covid19cellatlas.org/", "format": "h5ad", "source": "10x Genomics", "public_id": "E-MTAB-10026", "description": "TCR sequencing data from PBMCs, processed with Cell Ranger v4.0.0 and clonotype calling."}, {"id": "data_4", "omics": "Immunomics (BCR)", "link": "https://covid19cellatlas.org/", "format": "h5ad", "source": "10x Genomics", "public_id": "E-MTAB-10026", "description": "BCR sequencing data with V(D)J analysis, germline reconstruction, and clonotype network analysis."}, {"id": "data_5", "omics": "Multi-omics", "link": "https://covid19cellatlas.org/", "format": "h5ad", "source": "Integrated transcriptomics, proteomics, and immunomics", "public_id": "E-MTAB-10026", "description": "Harmonized dataset integrating transcriptome, proteome, TCR, and BCR data using Harmony batch correction and UMAP embedding."}], "analyses": [{"id": "analysis_1", "analysis_type": "Single-cell transcriptome and surface proteome analysis", "analysis_data": ["data_1", "data_2"], "training_set": [], "test_set": [], "label": {"severity": ["healthy", "asymptomatic", "mild", "moderate", "severe", "critical"]}}, {"id": "analysis_2", "analysis_type": "Cell clustering and annotation", "analysis_data": ["data_1", "data_2", "data_3", "data_4"], "training_set": [], "test_set": [], "label": {"condition": ["healthy", "asymptomatic", "mild", "moderate", "severe", "critical"]}}, {"id": "analysis_3", "analysis_type": "Differential abundance testing", "analysis_data": ["data_1", "data_2", "data_3", "data_4"], "training_set": [], "test_set": [], "label": {"severity": ["healthy", "asymptomatic", "mild", "moderate", "severe", "critical"]}, "metric": "Quasi-likelihood F-test", "value": "10% FDR"}, {"id": "analysis_4", "analysis_type": "Gene Set Enrichment Analysis (GSEA)", "analysis_data": ["data_1", "data_2", "data_3", "data_4"], "training_set": [], "test_set": [], "label": {"severity": ["healthy", "asymptomatic", "mild", "moderate", "severe", "critical"]}, "metric": "Normalized Enrichment Score (NES)", "value": "0.75 for IFNγ response, IL-6–JAK–STAT3 signaling"}, {"id": "analysis_5", "analysis_type": "Cydar analysis", "analysis_data": ["data_2"], "training_set": [], "test_set": [], "label": {"severity": ["healthy", "asymptomatic", "mild", "moderate", "severe", "critical"]}}, {"id": "analysis_6", "analysis_type": "TCR clonality analysis", "analysis_data": ["data_3"], "training_set": [], "test_set": [], "label": {"severity": ["healthy", "asymptomatic", "mild", "moderate", "severe", "critical"]}}, {"id": "analysis_7", "analysis_type": "BCR clonality and mutation analysis", "analysis_data": ["data_4"], "training_set": [], "test_set": [], "label": {"gender": ["female", "male"], "severity": ["healthy", "asymptomatic", "mild", "moderate", "severe", "critical"]}, "metric": "Clonotype size and Gini index", "value": "IGHV1-46 gene usage in women with critical disease"}, {"id": "analysis_8", "analysis_type": "Interferon, TNF, and JAK–STAT response scoring", "analysis_data": ["data_1"], "training_set": [], "test_set": [], "label": {"severity": ["healthy", "asymptomatic", "mild", "moderate", "severe", "critical"]}}, {"id": "analysis_9", "analysis_type": "kBET analysis", "analysis_data": ["data_1", "data_2"], "training_set": [], "test_set": [], "label": {"batch_factor": ["site"]}, "metric": "Wilcoxon paired signed-rank test", "value": "P < 2.1 × 10⁻⁸ (rejection rate improvement after Harmony integration)"}, {"id": "analysis_10", "analysis_type": "Bronchoalveolar lavage (BAL) data comparison", "analysis_data": ["data_1", "data_2"], "training_set": [], "test_set": [], "label": {"source": ["GSE145926"]}, "metric": "Transcriptomic similarity", "value": "CD16+ monocytes align with BAL macrophages via type I IFN response genes (C1QA/B/C, FCGR3A)"}, {"id": "analysis_11", "analysis_type": "CellPhoneDB receptor-ligand interaction analysis", "analysis_data": ["data_2"], "training_set": [], "test_set": [], "label": {"cell_type": ["monocytes", "platelets"]}, "metric": "Interaction strength", "value": "SIRPA:CD47, FPR1:ANXA1, FPR2:APP, ICAM1 interactions"}, {"id": "analysis_12", "analysis_type": "Platelet activation analysis", "analysis_data": ["data_2"], "training_set": [], "test_set": [], "label": {"condition": ["healthy", "asymptomatic", "mild", "moderate", "severe", "critical"]}, "metric": "Platelet activation markers", "value": "Increased PF4, GP9, STXBP2, CD34+ HSPCs"}, {"id": "analysis_13", "analysis_type": "HSPC commitment scoring", "analysis_data": ["data_1", "data_2"], "training_set": [], "test_set": [], "label": {"severity": ["healthy", "asymptomatic", "mild", "moderate", "severe", "critical"]}, "metric": "ANOVA with Tukey’s test", "value": "P = 2.92 × 10⁻¹⁸ (TE:EM ratio)"}, {"id": "analysis_14", "analysis_type": "Multiplex cytokine analysis", "analysis_data": ["data_2"], "training_set": [], "test_set": [], "label": {"severity": ["healthy", "asymptomatic", "mild", "moderate", "severe", "critical"]}, "metric": "Cytokine levels", "value": "CCL4, CXCL10, IL-7, IL-1α"}, {"id": "analysis_15", "analysis_type": "Restimulation of PBMCs with SARS-CoV-2 peptide", "analysis_data": ["data_1", "data_2", "data_3"], "training_set": [], "test_set": [], "label": {"condition": ["healthy", "asymptomatic", "mild", "moderate", "severe", "critical"]}, "metric": "Fold change", "value": "CD137 and CD107a upregulation in CD8+ T cells"}, {"id": "analysis_16", "analysis_type": "Flow cytometry validation", "analysis_data": ["data_1", "data_2", "data_3"], "training_set": [], "test_set": [], "label": {"condition": ["healthy", "asymptomatic", "mild", "moderate", "severe", "critical"]}, "metric": "Percentage of cells", "value": "50,000–60,000 cells per pool"}, {"id": "analysis_17", "analysis_type": "Differential correlation analysis", "analysis_data": ["data_1", "data_2"], "training_set": [], "test_set": [], "label": {"condition": ["healthy", "asymptomatic", "mild", "moderate", "severe", "critical"]}, "metric": "Pearson correlation", "value": "0.8 (TFH-plasmablast correlation loss in severe disease)"}], "results": [{"analysis_id": "analysis_1", "metric": "Fold change", "value": "200,000 cells per donor", "features": ["CD14+ monocytes", "CD16+ monocytes", "plasmablasts", "B cells", "CD8+ T cells", "CD4+ T cells", "NK cells", "HSPCs"]}, {"analysis_id": "analysis_2", "metric": "Number of cell clusters and subpopulations", "value": "18 cell subsets, 27 cell states", "features": ["proliferating monocytes", "innate lymphoid cell subpopulations", "isotype-specific plasma cells"]}, {"analysis_id": "analysis_3", "metric": "Odds ratio", "value": "1.81 (CD8+ T cells), 0.87 (CD8+ TEM cells)", "features": ["CD8+ T cells", "CD8+ TEM cells", "plasmablasts", "plasma cells"]}, {"analysis_id": "analysis_4", "metric": "Normalized Enrichment Score (NES)", "value": "0.75 for IFNγ response, IL-6–JAK–STAT3 signaling", "features": ["IL-2–STAT5 signaling", "mTORC1 signaling", "inflammatory response", "IFNγ response", "IL-6–JAK–STAT3 signaling"]}, {"analysis_id": "analysis_5", "metric": "Spatial FDR", "value": "<0.05", "features": ["608 hyperspheres", "B cells", "plasma cells", "HSPCs"]}, {"analysis_id": "analysis_6", "metric": "Odds ratio", "value": "1.81 (CD8+ T cells), 0.87 (CD8+ TEM cells)", "features": ["CD8+ T cells", "CD8+ TEM cells", "TE:EM ratio"]}, {"analysis_id": "analysis_7", "metric": "Clonotype size and Gini index", "value": "IGHV1-46 gene usage in women with critical disease", "features": ["IGHV1-46 gene usage", "clonotype size gini indices", "node closeness centrality"]}, {"analysis_id": "analysis_8", "metric": "Normalized enrichment score (NES)", "value": "0.75 for type I/III IFN response", "features": ["Type I/III IFN response", "TNF signaling", "JAK–STAT response"]}, {"analysis_id": "analysis_9", "metric": "Wilcoxon paired signed-rank test", "value": "P < 2.1 × 10⁻⁸ (rejection rate improvement after integration)", "features": ["Improved mixing of cells by site"]}, {"analysis_id": "analysis_10", "metric": "Transcriptomic similarity", "value": "CD16+ monocytes align with BAL macrophages", "features": ["Similarity between CD16+ monocytes and BAL macrophages", "expression of FCGR3A", "C1QA/B/C", "type I IFN response genes"]}, {"analysis_id": "analysis_11", "metric": "Interaction strength", "value": "SIRPA:CD47, FPR1:ANXA1, FPR2:APP, ICAM1 interactions", "features": ["SIRPA:CD47", "FPR1:ANXA1", "FPR2:APP", "ICAM1 interactions"]}, {"analysis_id": "analysis_12", "metric": "Platelet activation markers", "value": "Increased PF4, GP9, STXBP2, CD34+ HSPCs", "features": ["Platelet activation markers", "PF4", "GP9", "STXBP2", "CD34+ HSPCs"]}, {"analysis_id": "analysis_13", "metric": "ANOVA with Tukey’s test", "value": "P = 2.92 × 10⁻¹⁸ (TE:EM ratio)", "features": ["TE:EM ratio", "CD8+ T cell differentiation", "CD8+ TTE", "CD8+ TEM"]}, {"analysis_id": "analysis_14", "metric": "Cytokine levels", "value": "CCL4, CXCL10, IL-7, IL-1α", "features": ["CCL4", "CXCL10", "IL-7", "IL-1α"]}, {"analysis_id": "analysis_15", "metric": "Fold change", "value": "CD137 and CD107a upregulation in SARS-CoV-2 peptide-stimulated CD8+ T cells", "features": ["CD137", "CD107a", "CD8+ T cell activation"]}, {"analysis_id": "analysis_16", "metric": "Percentage of cells", "value": "50,000–60,000 cells per pool", "features": ["CD137", "CD107a", "CD8+ T cell activation"]}, {"analysis_id": "analysis_17", "metric": "Pearson correlation", "value": "0.8 (TFH-plasmablast correlation loss in severe disease)", "features": ["TFH and plasmablast/plasma cell correlation", "loss in severe disease"]}]}